Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone

G. Giavaresi, M. Fini, S. Gnudi, N. Nicoli Aldini, M. Rocca, A. Carpi, R. Giardino

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The effects of calcitonin, alendronate and fluorophosphate preventive treatment on ovariectomized rat femur were studied by comparing densitometric, mechanical, mineralogical and histomorphometric data. Sixty retired breeder female Sprague-Dawley rats, aged 10 months, were randomly divided into six groups. A group (baseline) was euthanized at the beginning of the study as a baseline group; four groups were ovariectomized and one was sham-operated (sham) and considered as a sham-aged group. A group of ovariectomized rats was used as a sham-therapy control (OVX) and received only deionized drinking water, while the other three received: a) salmon calcitonin (SCN) at a dose of 2 IU/kg/d s.c. (OVX + SCN); b) alendronate sodium salt (ALN) at a dose of 6 μg/kg/d administered by gavage (OVX + ALN); and c) L-glutamine monofluorophosphate (G-MFP) and calcium at a rate of 1:30 F/Ca at a dose of 0.21 mg F/6.30 mg Ca per kg/d by gavage (OVX + MFP). Significant increases (P <0.05) of about 15 and 27% in femoral proximal epiphysis bone mineral density (BMD) of the OVX + ALN group were observed versus healthy groups and the OVX group, respectively. The OVX + ALN group also showed significant increases in femoral mid-diaphysis BMD when compared to OVX (18%, P <0.001), OVX + SCN (14%, P <0.05) and OVX + MFP (18%, P <0.001) groups. In the OVX + MFP group, the three-point bending test demonstrated significant increases (P <0.05) in maximal load of 21 and 22% when compared to the OVX and OVX + SCN groups, respectively. Also, stiffness data showed significant increases of the OVX + MFP (17%) and sham (14%) groups in comparison with the OVX group. A decrease in Mg (42%, P <0.05), and increases in Ca (15%, P <0.0001) and PO 4 (8%, P <0.005) content were found by comparing OVX + MFP and OVX groups. Trabecular bone volume results showed significant increases by comparing OVX + ALN and OVX groups (12.20%, P <0.0005), as well as control groups. Tested agents were able to reduce the bone loss due to estrogen deficiency, but this did not always produce an increase in strength of the treated bone. Alendronate treatment prevented a decrease in bone mineral density and maintained bone mechanical properties after ovariectomy without impairment of bone mineralization in aged rats.

Original languageEnglish
Pages (from-to)397-403
Number of pages7
JournalBiomedicine and Pharmacotherapy
Volume55
Issue number7
DOIs
Publication statusPublished - 2001

Fingerprint

salmon calcitonin
fluorophosphate
Alendronate
Calcitonin
Bone Density
Bone and Bones
glutamine monofluorophosphate
Thigh
Physiologic Calcification
Diaphyses
Epiphyses
Ovariectomy
Drinking Water
Femur
Sprague Dawley Rats
Estrogens
Salts
Calcium
Control Groups

Keywords

  • Alendronate
  • Calcitonin
  • Osteoporosis
  • Ovariectomized rat
  • Sodium fluoride

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone. / Giavaresi, G.; Fini, M.; Gnudi, S.; Nicoli Aldini, N.; Rocca, M.; Carpi, A.; Giardino, R.

In: Biomedicine and Pharmacotherapy, Vol. 55, No. 7, 2001, p. 397-403.

Research output: Contribution to journalArticle

@article{1e238ca5476f4a4bb72c921fb81ec586,
title = "Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone",
abstract = "The effects of calcitonin, alendronate and fluorophosphate preventive treatment on ovariectomized rat femur were studied by comparing densitometric, mechanical, mineralogical and histomorphometric data. Sixty retired breeder female Sprague-Dawley rats, aged 10 months, were randomly divided into six groups. A group (baseline) was euthanized at the beginning of the study as a baseline group; four groups were ovariectomized and one was sham-operated (sham) and considered as a sham-aged group. A group of ovariectomized rats was used as a sham-therapy control (OVX) and received only deionized drinking water, while the other three received: a) salmon calcitonin (SCN) at a dose of 2 IU/kg/d s.c. (OVX + SCN); b) alendronate sodium salt (ALN) at a dose of 6 μg/kg/d administered by gavage (OVX + ALN); and c) L-glutamine monofluorophosphate (G-MFP) and calcium at a rate of 1:30 F/Ca at a dose of 0.21 mg F/6.30 mg Ca per kg/d by gavage (OVX + MFP). Significant increases (P <0.05) of about 15 and 27{\%} in femoral proximal epiphysis bone mineral density (BMD) of the OVX + ALN group were observed versus healthy groups and the OVX group, respectively. The OVX + ALN group also showed significant increases in femoral mid-diaphysis BMD when compared to OVX (18{\%}, P <0.001), OVX + SCN (14{\%}, P <0.05) and OVX + MFP (18{\%}, P <0.001) groups. In the OVX + MFP group, the three-point bending test demonstrated significant increases (P <0.05) in maximal load of 21 and 22{\%} when compared to the OVX and OVX + SCN groups, respectively. Also, stiffness data showed significant increases of the OVX + MFP (17{\%}) and sham (14{\%}) groups in comparison with the OVX group. A decrease in Mg (42{\%}, P <0.05), and increases in Ca (15{\%}, P <0.0001) and PO 4 (8{\%}, P <0.005) content were found by comparing OVX + MFP and OVX groups. Trabecular bone volume results showed significant increases by comparing OVX + ALN and OVX groups (12.20{\%}, P <0.0005), as well as control groups. Tested agents were able to reduce the bone loss due to estrogen deficiency, but this did not always produce an increase in strength of the treated bone. Alendronate treatment prevented a decrease in bone mineral density and maintained bone mechanical properties after ovariectomy without impairment of bone mineralization in aged rats.",
keywords = "Alendronate, Calcitonin, Osteoporosis, Ovariectomized rat, Sodium fluoride",
author = "G. Giavaresi and M. Fini and S. Gnudi and {Nicoli Aldini}, N. and M. Rocca and A. Carpi and R. Giardino",
year = "2001",
doi = "10.1016/S0753-3322(01)00069-5",
language = "English",
volume = "55",
pages = "397--403",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "7",

}

TY - JOUR

T1 - Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone

AU - Giavaresi, G.

AU - Fini, M.

AU - Gnudi, S.

AU - Nicoli Aldini, N.

AU - Rocca, M.

AU - Carpi, A.

AU - Giardino, R.

PY - 2001

Y1 - 2001

N2 - The effects of calcitonin, alendronate and fluorophosphate preventive treatment on ovariectomized rat femur were studied by comparing densitometric, mechanical, mineralogical and histomorphometric data. Sixty retired breeder female Sprague-Dawley rats, aged 10 months, were randomly divided into six groups. A group (baseline) was euthanized at the beginning of the study as a baseline group; four groups were ovariectomized and one was sham-operated (sham) and considered as a sham-aged group. A group of ovariectomized rats was used as a sham-therapy control (OVX) and received only deionized drinking water, while the other three received: a) salmon calcitonin (SCN) at a dose of 2 IU/kg/d s.c. (OVX + SCN); b) alendronate sodium salt (ALN) at a dose of 6 μg/kg/d administered by gavage (OVX + ALN); and c) L-glutamine monofluorophosphate (G-MFP) and calcium at a rate of 1:30 F/Ca at a dose of 0.21 mg F/6.30 mg Ca per kg/d by gavage (OVX + MFP). Significant increases (P <0.05) of about 15 and 27% in femoral proximal epiphysis bone mineral density (BMD) of the OVX + ALN group were observed versus healthy groups and the OVX group, respectively. The OVX + ALN group also showed significant increases in femoral mid-diaphysis BMD when compared to OVX (18%, P <0.001), OVX + SCN (14%, P <0.05) and OVX + MFP (18%, P <0.001) groups. In the OVX + MFP group, the three-point bending test demonstrated significant increases (P <0.05) in maximal load of 21 and 22% when compared to the OVX and OVX + SCN groups, respectively. Also, stiffness data showed significant increases of the OVX + MFP (17%) and sham (14%) groups in comparison with the OVX group. A decrease in Mg (42%, P <0.05), and increases in Ca (15%, P <0.0001) and PO 4 (8%, P <0.005) content were found by comparing OVX + MFP and OVX groups. Trabecular bone volume results showed significant increases by comparing OVX + ALN and OVX groups (12.20%, P <0.0005), as well as control groups. Tested agents were able to reduce the bone loss due to estrogen deficiency, but this did not always produce an increase in strength of the treated bone. Alendronate treatment prevented a decrease in bone mineral density and maintained bone mechanical properties after ovariectomy without impairment of bone mineralization in aged rats.

AB - The effects of calcitonin, alendronate and fluorophosphate preventive treatment on ovariectomized rat femur were studied by comparing densitometric, mechanical, mineralogical and histomorphometric data. Sixty retired breeder female Sprague-Dawley rats, aged 10 months, were randomly divided into six groups. A group (baseline) was euthanized at the beginning of the study as a baseline group; four groups were ovariectomized and one was sham-operated (sham) and considered as a sham-aged group. A group of ovariectomized rats was used as a sham-therapy control (OVX) and received only deionized drinking water, while the other three received: a) salmon calcitonin (SCN) at a dose of 2 IU/kg/d s.c. (OVX + SCN); b) alendronate sodium salt (ALN) at a dose of 6 μg/kg/d administered by gavage (OVX + ALN); and c) L-glutamine monofluorophosphate (G-MFP) and calcium at a rate of 1:30 F/Ca at a dose of 0.21 mg F/6.30 mg Ca per kg/d by gavage (OVX + MFP). Significant increases (P <0.05) of about 15 and 27% in femoral proximal epiphysis bone mineral density (BMD) of the OVX + ALN group were observed versus healthy groups and the OVX group, respectively. The OVX + ALN group also showed significant increases in femoral mid-diaphysis BMD when compared to OVX (18%, P <0.001), OVX + SCN (14%, P <0.05) and OVX + MFP (18%, P <0.001) groups. In the OVX + MFP group, the three-point bending test demonstrated significant increases (P <0.05) in maximal load of 21 and 22% when compared to the OVX and OVX + SCN groups, respectively. Also, stiffness data showed significant increases of the OVX + MFP (17%) and sham (14%) groups in comparison with the OVX group. A decrease in Mg (42%, P <0.05), and increases in Ca (15%, P <0.0001) and PO 4 (8%, P <0.005) content were found by comparing OVX + MFP and OVX groups. Trabecular bone volume results showed significant increases by comparing OVX + ALN and OVX groups (12.20%, P <0.0005), as well as control groups. Tested agents were able to reduce the bone loss due to estrogen deficiency, but this did not always produce an increase in strength of the treated bone. Alendronate treatment prevented a decrease in bone mineral density and maintained bone mechanical properties after ovariectomy without impairment of bone mineralization in aged rats.

KW - Alendronate

KW - Calcitonin

KW - Osteoporosis

KW - Ovariectomized rat

KW - Sodium fluoride

UR - http://www.scopus.com/inward/record.url?scp=0034806981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034806981&partnerID=8YFLogxK

U2 - 10.1016/S0753-3322(01)00069-5

DO - 10.1016/S0753-3322(01)00069-5

M3 - Article

C2 - 11669503

AN - SCOPUS:0034806981

VL - 55

SP - 397

EP - 403

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 7

ER -